CareLit · DOI-Nachweis · Pneumologie
Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies
DOI 10.1055/s-0035-1544637
Bibliografische Angaben
Nachweis in CareLit
Autor:innenR Buhl, E Derom, G Ferguson, F Maltais, E Pizzichini, J Reid, H Watz, L Groenke, A Hamilton, K Tetzlaff, L Korducki, H Huisman, S Waitere-Wijker, E Bateman
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Tiotropium (T), a once-daily long-acting muscarinic antagonist, is a well-established first-line maintenance treatment in chronic obstructive pulmonary disease (COPD); olodaterol (O) is a once-daily long-acting ß2-agonist that has recently gained approval in several countries. Two Phase III replicate pivotal studies assessed the efficacy and safety of fixed-dose combinations of T and O (T+O) delivered…
Zitieren
Zitierempfehlung
R Buhl, E Derom, G Ferguson, F Maltais, E Pizzichini, J Reid, H Watz, L Groenke, A Hamilton, K Tetzlaff, L Korducki, H Huisman, S Waitere-Wijker, E Bateman (2015) Once-daily tiotropium and olodaterol fixed-dose combination via the Respimat improves outcomes vs mono-components in COPD in two 1-year studies. Pneumologie (02). https://doi.org/10.1055/s-0035-1544637
Mit CareLit weiterarbeiten